Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04205630 · ClinicalTrials.gov registry record · Phase 2
SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma
A Phase 2 study of Endometrial Cancer, sponsored by Byondis B.V..
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 20
- Study locations
NCT04205630 is a Phase 2 study of Endometrial Cancer that has completed, run by Byondis B.V.. The registered enrollment target is 64 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 2 states.
The verdict
NCT04205630, a Phase 2 study of Endometrial Cancer, has completed, sponsored by Byondis B.V..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of SYD985 in recurrent, advanced or metastatic endometrial cancer.
Conditions Studied
Interventions
- DRUG SYD985
Study Locations (20)
Other
- MedTrials - Krakow
- St. John of Dukla Oncology Center of Lublin Land - Lublin
- Arkhangelsk Clinical Oncology Center - Arkhangelsk
- Chelyabinsk Regional Clinical Oncology and Nuclear Medicine Center - Chelyabinsk
- Regional Oncology Center - Irkutsk
- Clinical Oncology Center - Omsk
- Orenburg Regional Clinical Oncology Center - Orenburg
- Oncology Center of Moskovskiy District - Saint Petersburg
- Private Medical Institution "EVROMEDSERVIS" - Saint Petersburg
- AV Medical Group - Saint Petersburg
- Oncology Center #2 - Sochi
- Tambov Regional Oncological Clinical Center - Tambov
- Republican Clinical Oncology Center - Ufa
- Volgograd Regional Clinical Oncology Center - Volgograd
- National Cancer Research Center - Belgrade
- Oncology Institute of Vojvodina (IOV), Clinic of Surgical Oncology, Department of Gynecology - Kamenitz
- Clinical Center Nis, Clinic of Oncology - Niš
- National University Hospital, Department of Hematology-Oncology - Singapore
- National Cancer Centre Singapore - Singapore
Connecticut
- Smilow Cancer Hospital (Yale) - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2020-05-28 |
| Est. Completion | 2023-04-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04205630
The ClinicalTrials.gov registry entry for NCT04205630 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (88% lower). The listed sponsor is Byondis B.V., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which SYD985 is the first listed.
NCT04205630 reports 20 study locations spanning 2 distinct geographic areas - top geographies include Other, Connecticut.
Frequently Asked Questions
What is clinical trial NCT04205630 about?
NCT04205630 is a clinical study titled "SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma". The purpose of this study is to evaluate the safety and efficacy of SYD985 in recurrent, advanced or metastatic endometrial cancer.
What is the current status of trial NCT04205630?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2020-05-28. Estimated completion is 2023-04-25.
What conditions does trial NCT04205630 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT04205630?
The interventions under investigation include: SYD985 (DRUG).
Who is sponsoring clinical trial NCT04205630?
This trial is sponsored by Byondis B.V., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04205630 being conducted?
This trial has 20 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
RECRUITING · Phase 2
-
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
RECRUITING · Phase 2
-
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RECRUITING · Phase 2
-
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.